A Prognostic Model of Alzheimer's Disease Relying on Multiple Longitudinal Measures and Time-to-event Data

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2018 Jan 8

PMID 29306668

Citations 14

Authors

Kan Li

Richard OBrien

Michael Lutz

Sheng Luo

Affiliations

Soon will be listed here.

Abstract

Introduction: Characterizing progression in Alzheimer's disease is critically important for early detection and targeted treatment. The objective was to develop a prognostic model, based on multivariate longitudinal markers, for predicting progression-free survival in patients with mild cognitive impairment.

Methods: The information contained in multiple longitudinal markers was extracted using multivariate functional principal components analysis and used as predictors in the Cox regression models. Cross-validation was used for selecting the best model based on Alzheimer's Disease Neuroimaging Initiative-1. External validation was conducted on Alzheimer's Disease Neuroimaging Initiative-2.

Results: Model comparison yielded a prognostic index computed as the weighted combination of historical information of five neurocognitive longitudinal markers that are routinely collected in observational studies. The comprehensive validity analysis provided solid evidence of the usefulness of the model for predicting Alzheimer's disease progression.

Discussion: The prognostic model was improved by incorporating multiple longitudinal markers. It is useful for monitoring disease and identifying patients for clinical trial recruitment.

Citing Articles

Neuroimaging techniques, gene therapy, and gut microbiota: frontier advances and integrated applications in Alzheimer's Disease research.

Wang H, Shi C, Jiang L, Liu X, Tang R, Tang M Front Aging Neurosci. 2024; 16:1485657.

PMID: 39691161 PMC: 11649678. DOI: 10.3389/fnagi.2024.1485657.

The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making.

Starling M, Kehoe L, Burnett B, Green P, Venkatakrishnan K, Madabushi R Clin Pharmacol Ther. 2024; 117(2):343-352.

PMID: 39410710 PMC: 11739755. DOI: 10.1002/cpt.3467.

Deep learning model for individualized trajectory prediction of clinical outcomes in mild cognitive impairment.

Jung W, Kim S, Kim J, Jang H, Park C, Kim H Front Aging Neurosci. 2024; 16:1356745.

PMID: 38813529 PMC: 11135285. DOI: 10.3389/fnagi.2024.1356745.

Predicting Alzheimer's Disease and Quantifying Asymmetric Degeneration of the Hippocampus Using Deep Learning of Magnetic Resonance Imaging Data.

Liu X, Li H, Fan Y Proc IEEE Int Symp Biomed Imaging. 2023; 2023.

PMID: 37790879 PMC: 10544795. DOI: 10.1109/isbi53787.2023.10230830.

Constructing a prognostic risk model for Alzheimer's disease based on ferroptosis.

Wang X, Zhai R, Li Z, Li H, Lei Y, Zhao F Front Aging Neurosci. 2023; 15:1168840.

PMID: 37181620 PMC: 10172508. DOI: 10.3389/fnagi.2023.1168840.

References

Li K, Chan W, Doody R, Quinn J, Luo S . Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data. J Alzheimers Dis. 2017; 58(2):361-371. PMC: 5477671. DOI: 10.3233/JAD-161201. View

Collins G, de Groot J, Dutton S, Omar O, Shanyinde M, Tajar A . External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol. 2014; 14:40. PMC: 3999945. DOI: 10.1186/1471-2288-14-40. View

Shaw L, Vanderstichele H, Knapik-Czajka M, Clark C, Aisen P, Petersen R . Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009; 65(4):403-13. PMC: 2696350. DOI: 10.1002/ana.21610. View

Li S, Okonkwo O, Albert M, Wang M . Variation in Variables that Predict Progression from MCI to AD Dementia over Duration of Follow-up. Am J Alzheimers Dis (Columbia). 2014; 2(1):12-28. PMC: 3919474. DOI: 10.7726/ajad.2013.1002. View

Debray T, Vergouwe Y, Koffijberg H, Nieboer D, Steyerberg E, Moons K . A new framework to enhance the interpretation of external validation studies of clinical prediction models. J Clin Epidemiol. 2014; 68(3):279-89. DOI: 10.1016/j.jclinepi.2014.06.018. View

Holte S, Randolph T, Ding J, Tien J, McClelland R, Baeten J . Efficient use of longitudinal CD4 counts and viral load measures in survival analysis. Stat Med. 2012; 31(19):2086-97. PMC: 3641845. DOI: 10.1002/sim.5318. View

Gauthier S, Wu L, Rosa-Neto P, Jia J . Prevention strategies for Alzheimer's disease. Transl Neurodegener. 2012; 1(1):13. PMC: 3514088. DOI: 10.1186/2047-9158-1-13. View

Petersen R, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E . Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56(3):303-8. DOI: 10.1001/archneur.56.3.303. View

Fleisher A, Sowell B, Taylor C, Gamst A, Petersen R, Thal L . Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007; 68(19):1588-95. DOI: 10.1212/01.wnl.0000258542.58725.4c. View

10.

Kong D, Giovanello K, Wang Y, Lin W, Lee E, Fan Y . Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data. J Alzheimers Dis. 2015; 46(3):695-702. PMC: 4583331. DOI: 10.3233/JAD-150164. View

11.

Gomar J, Bobes-Bascaran M, Conejero-Goldberg C, Davies P, Goldberg T . Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry. 2011; 68(9):961-9. DOI: 10.1001/archgenpsychiatry.2011.96. View

12.

Lo R, Hubbard A, Shaw L, Trojanowski J, Petersen R, Aisen P . Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011; 68(10):1257-66. PMC: 5604752. DOI: 10.1001/archneurol.2011.123. View

13.

Cui Y, Liu B, Luo S, Zhen X, Fan M, Liu T . Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS One. 2011; 6(7):e21896. PMC: 3140993. DOI: 10.1371/journal.pone.0021896. View

14.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

15.

Simon R, Subramanian J, Li M, Menezes S . Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data. Brief Bioinform. 2011; 12(3):203-14. PMC: 3105299. DOI: 10.1093/bib/bbr001. View

16.

Ewers M, Walsh C, Trojanowski J, Shaw L, Petersen R, Jack Jr C . Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging. 2010; 33(7):1203-14. PMC: 3328615. DOI: 10.1016/j.neurobiolaging.2010.10.019. View

17.

Devanand D, Liu X, Tabert M, Pradhaban G, Cuasay K, Bell K . Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry. 2008; 64(10):871-9. PMC: 2613777. DOI: 10.1016/j.biopsych.2008.06.020. View

18.

Zhang D, Shen D . Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One. 2012; 7(3):e33182. PMC: 3310854. DOI: 10.1371/journal.pone.0033182. View

19.

Barnes D, Cenzer I, Yaffe K, Ritchie C, Lee S . A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease. Alzheimers Dement. 2014; 10(6):646-55. PMC: 4119093. DOI: 10.1016/j.jalz.2013.12.014. View

20.

Gerds T, Schumacher M . Consistent estimation of the expected Brier score in general survival models with right-censored event times. Biom J. 2007; 48(6):1029-40. DOI: 10.1002/bimj.200610301. View